title: Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis.
abstract: Selective serotonin reuptake inhibitors (SSRIs) are frequently used to treat depression during pregnancy and the postpartum period. These drugs are capable of crossing the placenta and being transferred to the newborn during lactation. This report reviews the available information regarding the effects of SSRIs on the fetus and newborn; including long-term neurodevelopmental outcomes.
authors: Department of Pediatrics, Division of Neonatal-Perinatal Medicine, University of Michigan, Ann Arbor, MI 48109-0254, USA.
authors: Keri A
authors: KA
authors: Lattimore
authors: Steven M
authors: SM
authors: Donn
authors: Niko
authors: N
authors: Kaciroti
authors: Alex R
authors: AR
authors: Kemper
authors: Charles R
authors: CR
authors: Neal
authors: Delia M
authors: DM
authors: Vazquez
mesh_terms: D002657:Child Development / Q000187:drug effects; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn / Q000502:physiology*; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors